FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biotechnology, namely to novel IL-17-inhibiting polypeptides, corresponding to fused proteins, to compositions and their application for medicinal purposes. Polypeptide contains amino acid sequence, which is selected from group, consisting of GVTLFVALYD YKAFWPGDLS FHKGEKFQIL RTSDGDWWEA RSLTTGETGY IPSNYVAPVD SIQ (SEQ ID NO: 39), GVTLFVALYD YKAFWPGDIS FHKGEKFQIL RTSDGEWWVA RSLTTGEEGY IPSNYVAPVD SIQ (SEQ ID NO: 57) or GVTLFVALYD YKAFWPGDIS FHKGEKFQIL RTSDGEWWIA RSLTTGEEGY IPSNYVAPVD SIQ (SEQ ID NO: 107); amino acid sequence, which has, at least, 80%, preferably, at least, 90%, more preferably, at least, 95% identity of amino acid sequence with SEQ ID NO: 39, SEQ ID NO:57 or SEQ ID NO: 107; fragment or functional derivative of SEQ ID NO: 39, SEQ ID NO: 57 or SEQ ID NO: 107, obtained due to substitution, addition and/or removal of not more than 5 amino acids.
EFFECT: invention makes it possible to bind IL-17 with high specificity and affinity.
33 cl, 17 dwg, 3 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-FYNOMER CONJUGATES | 2015 |
|
RU2732226C2 |
| NEW BINDING MOLECULES WITH ANTI-TUMOUR ACTIVITY | 2013 |
|
RU2627185C1 |
| SPECIFIC AND HIGH-AFFINITY BINDING PROTEINS CONTAINING MODIFIED SH3-DOMAINS OF Fyn KINASE | 2007 |
|
RU2478707C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY | 2016 |
|
RU2727165C2 |
| METHOD OF MODIFICATION OF POLYPEPTIDE FOR PURIFICATION OF POLYPEPTIDE MULTIMERS | 2010 |
|
RU2606264C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| MODIFIED INTERLEUKIN-7 PROTEIN AND METHODS FOR USE THEREOF | 2016 |
|
RU2708160C2 |
